

# 11  
Yc  
12-7-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

Georgiev *et al.*

Appl. No. 09/462,625

§102(e) Date: July 28, 2000

For: **Tumor Growth Inhibition- and  
Apoptosis-Associated Genes and  
Polypeptides and Methods of Use  
Thereof**

Art Unit: 1642

Examiner: Rawlings, S.

Atty. Docket: 0652.1630001/AGU

RECEIVED  
DEC 5 0 2001  
TECH CENTER 1600/2900

**First Supplemental Information Disclosure Statement**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 is a document that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on March 14, 2000, in connection with the above-captioned application. A copy of the document is also provided.

Applicants have listed a publication date on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication date should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search

has been made, or that information more material to the examination of the present patent application does not exist.

This First Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

Consideration of the cited document and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

*Andrea J. Kamage*  
*for* #43,703

Eric K. Steffe  
Attorney for Applicants  
Registration No. 36,688

Date: 12/3/01

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600